<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109265">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01908764</url>
  </required_header>
  <id_info>
    <org_study_id>C-13-023</org_study_id>
    <nct_id>NCT01908764</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery</brief_title>
  <official_title>An Open-Label, Single Dose, Pharmacokinetic Study of AL-60371 Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the pharmacokinetics of AL-60371 otic suspension
      following two posologies of bilateral ototopical doses in pediatric subjects immediately
      after bilateral tympanostomy tube surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Maximum observed analyte plasma concentration (Cmax)</measure>
    <time_frame>Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the analyte plasma concentration-time curve to the last quantifiable sampling time point (AUC0-last)</measure>
    <time_frame>Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from 0 to infinity (AUC0-∞)</measure>
    <time_frame>Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to last measurable concentration (Tlast)</measure>
    <time_frame>Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The terminal elimination half (T½)</measure>
    <time_frame>Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Otitis Media</condition>
  <arm_group>
    <arm_group_label>AL-60371/Posology 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-60371/Posology 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-60371 otic suspension</intervention_name>
    <arm_group_label>AL-60371/Posology 1</arm_group_label>
    <arm_group_label>AL-60371/Posology 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requires bilateral myringotomy and tympanostomy tube insertion;

          -  Provides informed consent (parent/legal guardian);

          -  Signs assent form where applicable (subject);

          -  Accompanied by parent/legal guardian at each visit;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Menarcheal females;

          -  Current or recent history of any disease which, in the opinion of the Principal
             Investigator, may place the subject at risk or interfere with study;

          -  Use of excluded medications within one week prior to surgery and for the duration of
             the study;

          -  Requires another surgical procedure in addition to the myringotomy;

          -  Clinically relevant otic condition which, in the opinion of the Principal
             Investigator, would preclude the safe administration of the study medication;

          -  Participation in any other investigational study within 30 days before entry into
             this study or along with this study;

          -  Known or suspected allergy or hypersensitivity to any active or inactive ingredient
             in the test article;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celeste McClean, BS, MT (ASCP)</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>July 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ear tubes</keyword>
  <keyword>tympanostomy tubes</keyword>
  <keyword>Otitis Media at the time of Tympanostomy Tube surgery</keyword>
  <keyword>OMTT</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
